|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400081125 |
|
最近更新日期: Date of Last Refreshed on: |
2024-02-23 09:05:39 |
|
注册时间: Date of Registration: |
2024-02-23 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
调冲补肾法治疗身心相关性疾病(焦虑状态)的临床观察 |
|
Public title: |
Clinical observation on the treatment of psychosomatic diseases (anxiety state) by regulating and tonifying kidney |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
调冲补肾法治疗身心相关性疾病(焦虑状态)的临床观察 |
|
Scientific title: |
Clinical observation on the treatment of psychosomatic diseases (anxiety state) by regulating and tonifying kidney |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
曹婧 |
研究负责人: |
曹婧 |
|
Applicant: |
Cao Jing |
Study leader: |
Cao Jing |
|
申请注册联系人电话: Applicant telephone: |
+86 156 2887 2627 |
研究负责人电话:
Study leader's |
+86 156 2887 2627 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
caojing15@163.com |
研究负责人电子邮件: Study leader's E-mail: |
caojing15@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
山东省济南市市中区经八路1号 |
研究负责人通讯地址: |
山东省济南市市中区经八路1号 |
|
Applicant address: |
No. 1, Jingba Road, Shizhong District, Jinan, Shandong Province |
Study leader's address: |
No. 1, Jingba Road, Shizhong District, Jinan, Shandong Province |
|
申请注册联系人邮政编码: Applicant postcode: |
250002 |
研究负责人邮政编码: Study leader's postcode: |
250002 |
|
申请人所在单位: |
山东中医药大学第二附属医院 |
||
|
Applicant's institution: |
The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine |
||
|
研究负责人所在单位: |
山东中医药大学第二附属医院 |
||
|
Affiliation of the Leader: |
The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023伦审-KY-015 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
山东中医药大学第二附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-03-27 00:00:00 | ||
|
伦理委员会联系人: |
陈守强 |
||
|
Contact Name of the ethic committee: |
Shouqiang Chen |
||
|
伦理委员会联系地址: |
山东省济南市市中区经八路1号 |
||
|
Contact Address of the ethic committee: |
No. 1, Jingba Road, Shizhong District, Jinan, Shandong Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 531 8243 6062 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
山东中医药大学第二附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
山东省济南市市中区经八路1号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 1, Jingba Road, Shizhong District, Jinan, Shandong Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Raise independently |
||||||||||||||||||||||
|
研究疾病: |
身心相关疾病(焦虑状态) |
||||||||||||||||||||||
|
Target disease: |
Psychosomatic diseases (anxiety state) |
||||||||||||||||||||||
|
研究疾病代码: |
No |
||||||||||||||||||||||
|
Target disease code: |
No |
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本项目拟通过调冲补肾法治疗身心相关性疾病(焦虑状态)的临床研究,经由脉-证-针-效对应评价,观察受试患者经治疗后临床有效率、焦虑自评量表(SAS)、汉密尔顿焦虑量表(HAMA)、系统辨证脉学脉诊信息测量表、中医证候评分的变化情况,为焦虑状态的患者从形神同治角度出发提供更佳的方法和科学依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
This project plans to conduct a clinical study on the treatment of psychosomatic related diseases (anxiety state) with Tiaochongbushen method. Through the corresponding evaluation of pulse, syndrome, acupuncture and effect, the changes of clinical effective rate, self-rating anxiety scale (SAS), Hamilton Anxiety Scale (HAMA), systematic syndrome differentiation, pulse learning and pulse diagnosis information scale, and TCM syndrome score of the tested patients after treatment are observed. To provide a better method and scientific basis for patients with anxiety from the perspective of treating body and spirit together. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
采用SAS、HAMA、脉诊量表进行评分,针刺组采用调冲补肾法进行针刺治疗,针具采用苏州医疗用品厂有限公司出产的华佗牌0.20×40mm的一次性无菌针灸针,选取穴位为百会、膻中、肓俞(双侧)、内关(双侧)、公孙(双侧)、照海(双侧),对照组采用口服抗焦虑药物盐酸丁螺环酮片(商品名:一舒,生产厂家:江苏恩华药业股份有限公司,规格:5mg/片,批准文号:国药准字H19991024),空白组只进行量表评价。疗程:针刺组:每次留针20min,每10min行针1次,TDP灯照射,每次行针30s,每周治疗5次,4周(一个疗程)后进行疗效判定。对照组:口服,第一周5mg/次,一日2次,早晚餐后1h口服,连续服用4周。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
The patients in the acupuncture group were treated with Tiao-chong Bushen method, and the disposable sterile acupuncture needles of Huatuo brand (0.20×40mm) produced by Suzhou Medical Supplies Factory Co., LTD were used. The acupoints selected were Baihui (GV 20), Danzhong (CV 17), Huangshu (bilateral), Neiguan (bilateral), Gongsun (bilateral) and Zhaohai (bilateral). The control group was treated with oral anti-anxiety drug buspirone hydrochloride tablets (trade name: Yichu, manufacturer: Jiangsu Enhua Pharmaceutical Co., LTD., specification: 5mg/ tablet, approval number: Chinese Medicine approval number H19991024), and the blank group was only evaluated by the scale. Treatment course: acupuncture group: the needles were retained for 20min each time, the needles were applied once every 10min, TDP lamp irradiation was performed for 30s each time, 5 times a week, and the curative effect was evaluated after 4 weeks (a course). Control group: oral administration, 5mg/ time, 2 times a day, 1 hour after breakfast and dinner for 4 weeks. |
||||||||||||||||||||||
|
纳入标准: |
(1)符合烦躁焦虑状态诊断标准; (2)男女均可,18岁≤年龄≤60岁; (3)有引起烦躁焦虑的生活、工作、感情等方面的事件且持续时间≥3个月; (4)50分≤焦虑自评量表(SAS)评分≤69分,7分≤汉密尔顿焦虑量表(HAMA)评分<21分,无精神障碍史、无重大躯体疾病; (5)无脑部器质性疾病及心、肝、肾功能正常者; (6)知情同意者。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Meet the diagnostic criteria of dysphoria and anxiety; (2) Male and female, 18 ≤ age ≤60 years old; (3) Patients have life, work, emotional and other events that caused anxiety and lasted for more than 3 months; (4)50 ≤ self-rating anxiety scale (SAS) score ≤69, 7 ≤ Hamilton Anxiety Scale (HAMA) score < 21, no history of mental disorders, no major physical diseases; (5)no brain organic disease and normal heart, liver, kidney function; (6) Informed consent. |
||||||||||||||||||||||
|
排除标准: |
(1)不愿意合作者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Unwilling to cooperate. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-12-01 00:00:00至 To 2024-11-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-02-01 00:00:00 至 To 2024-01-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由专人(此人不参与试验操作)严格按照诊断标准、纳入标准和排除标准筛选病例,纳入符合标准的采用随机数表法产生随机序列。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A special person (this person does not participate in the trial operation) shall screen the cases in strict accordance with the diagnostic criteria, inclusion criteria and exclusion criteria, and use the random number table method to generate the random sequence if the cases meet the criteria |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
No |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
Resman临床试验公共管理平台 http://www.medresman.org.cn/login.aspx |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Resman Clinical trial public management platform http://www.medresman.org.cn/login.aspx |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集和数据核实管理由不同的专人负责。数据采集记录病例记录表,数据管理由山东中医药大学第二附属医院系统中医整体诊疗团队储存。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection and verification management are handled by different dedicated personnel.Data Collection Record Case Record Form,Data management is stored by the overall TCM diagnosis and treatment team of the Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |